1. Scrip
  2. >>Focus On Asia
  3. >>China

Sandoz, Taiwan’s TLC Ink Commercialization Deal For AmBisome Generic In U.S., EU

 
• By Rebecca Kanthor

Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.

SHANGHAI – Taiwanese biopharmaceutical company Taiwan Liposome Co. Ltd. inked an agreement with Novartis AG generic subsidiary Sandoz International GMBH to commercialize its liposomal amphotericin B product in Taiwan, TLC announced Dec. 18.

Under the agreement, Sandoz will commercialize TLC’s liposomal amphotericin B product in the EU and U.S. The company declined to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.